INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

Review Paper

Gene Target Therapy for Male Breast Cancer

Preeti Bhunia*, Dr. Nakul Gupta, Dr. Md. Sarfaraz Alam, Kamal Bani, Aditi Singh, Aanchal Dahiya

IIMT College of Pharmacy, Greater Noida, UP – 201306

ARTICLE INFO

Published: 21 May. 2025
Keywords:
Male breast cancer, Gene-targeted therapy, Hormonal influences, Genetic mutations, PARP inhibitors, ADCs
DOI:
10.5281/zenodo.15480408

ABSTRACT

Male breast cancer, an infrequent yet significant condition, accounts for 1% of all breast cancer diagnoses. Traditional treatments for male breast cancer often mirror those used in female cases, primarily due to limited research focusing on men. However, advancements in gene-targeted therapies have introduced more precise and effective treatment options [1]. Gene-targeted therapy aims to identify and combat specific genetic mutations or proteins that promote cancer growth in male breast cancer. One prevalent target is the HER2 protein. In cases where cancer cells overexpress HER2, monoclonal antibodies such as Trastuzumab (Herceptin) and Pertuzumab (Perjeta) are utilized. These drugs bind directly to the HER2 proteins, blocking their activity and hindering cancer cell proliferation [2]. Hormonal influences also play a role in male breast cancer, with specific tumors exhibiting hormone receptor-positive characteristics. Targeted treatments for these types aim to obstruct hormone receptors or decrease hormone levels. Tamoxifen, a selective estrogen receptor modulator (SERM), is commonly prescribed due to its efficacy in treating hormone receptor-positive breast cancer in both men and women. Genetic mutations, particularly in BRCA1 and BRCA2 genes, are linked to around 20% of male breast cancer cases. This genetic predisposition has led to the development of PARP inhibitors like Olaparib. These drugs exploit the weaknesses in cancer cells caused by these mutations, providing targeted treatment options [3]. Innovative treatment methods like Antibody-Drug Conjugates (ADCs) combine monoclonal antibodies with chemotherapy agents. The antibodies direct the chemotherapy specifically to cancerous cells, minimizing damage to healthy tissues. Despite the promising outlook of gene-targeted therapies, they come with specific side effects distinct from traditional chemotherapy. For instance, HER2-targeted treatments can lead to heart issues, while hormone therapies may result in menopausal-like symptoms.

***Corresponding Author:** Preeti Bhunia
Address: *IIMT College of Pharmacy, Greater Noida, UP – 201306*
Email ✉: preetibhunia082@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Nonetheless, gene-targeted therapy marks a significant advancement in male breast cancer treatment, offering tailored approaches that can potentially improve patient outcomes. Ongoing research dedicated to male breast cancer is crucial for refining these therapies and enhancing survival rate.

INTRODUCTION

Male breast cancer represents a unique intersection of genetics, biology, and treatment paradigms that necessitates a deeper understanding of its distinct characteristics. While it is rare, its implications for male patients and their families can be profound, highlighting the need for increased awareness and research [4]. One critical aspect of male breast cancer is the role of awareness and early detection. Unlike female breast cancer, which is often screened through mammograms, men typically do not undergo routine breast cancer screenings. This lack of awareness can lead to delayed diagnoses, which may result in poorer outcomes [5]. Educational initiatives aimed at both healthcare providers and the public are essential to encourage men to recognize potential symptoms, such as unusual lumps or changes in breast tissue. Furthermore, the psychological impact of a male breast cancer diagnosis can be significant. Men may experience feelings of isolation or stigma, as breast cancer is traditionally viewed as a female disease. Support networks tailored specifically for men, including counselling and peer support groups, can play a vital role in addressing these emotional challenges and fostering a sense of community among those affected. Research into male breast cancer is gradually expanding, but it remains underfunded compared to female breast cancer studies. Advocacy for more research funding is crucial to uncover the biological differences between male and female breast cancers, which could lead to more personalized and effective treatment strategies. Additionally, understanding the environmental and lifestyle factors that may contribute to male breast cancer risk is an area ripe for exploration [6]. Traditional treatments for male breast cancer often mirror those used in female cases, primarily due to limited research focusing on men.However, advancements in gene-targeted therapies have introduced more precise and effective treatment options. Gene-targeted therapy has revolutionized the approach to treating male breast cancer, offering hope for more tailored and effective interventions. Beyond HER2-targeted therapies, ongoing research is exploring additional genetic markers that could influence treatment decisions. For instance, mutations in the PIK3CA gene, which are implicated in various cancers, including breast cancer, may also play a role in male cases. Targeting these mutations with specific inhibitors could provide another avenue for personalized treatment. Moreover, the integration of genomic profiling in clinical practice is becoming increasingly important. By analyzing the genetic makeup of a patient's tumor, oncologists can identify unique mutations and tailor therapies accordingly. This precision medicine approach not only enhances treatment efficacy but also minimizes unnecessary side effects by sparing patients from ineffective treatments [7].

The Role of Gene Targeted Therapy:

The role of gene-targeted therapy in male breast cancer extends beyond merely addressing specific mutations; it also encompasses the broader implications of personalized medicine. As our understanding of the genetic underpinnings of male breast cancer deepens, the potential for developing novel therapeutic agents tailored to individual genetic profiles becomes increasingly viable. This shift towards precision medicine not only enhances treatment efficacy but also empowers patients by involving them in their

treatment decisions based on their unique genetic makeup. Furthermore, the identification of additional biomarkers beyond BRCA1 and BRCA2 is crucial. For instance, research is beginning to uncover the significance of other genetic alterations, such as those in the ATM gene, which may also influence treatment responses. By expanding the repertoire of recognized genetic markers, clinicians can better stratify patients according to their risk profiles and tailor interventions accordingly [8] The integration of artificial intelligence and machine learning in analyzing genomic data presents an exciting frontier in gene-targeted therapy. These technologies can help identify patterns and predict treatment responses more accurately, leading to more informed clinical decisions. As data from genomic studies accumulate, the potential for AI to assist in real-time decision-making in clinical settings could revolutionize the management of male breast cancer. The collaborative efforts between oncologists, geneticists, and researchers are vital in translating laboratory findings into clinical practice. Multidisciplinary teams can ensure that the latest advancements in gene-targeted therapies are rapidly incorporated into treatment protocols, ultimately benefiting male breast cancer patients [9].

HER2-positive breast cancer:

HER2-positive breast cancer represents a distinct subtype characterized by the overexpression of the HER2 protein, which can lead to more aggressive tumor behavior. In men, this subtype may present unique challenges and opportunities for treatment. The development of targeted therapies, such as trastuzumab (Herceptin) and newer agents like neratinib, has revolutionized the management of HER2-positive breast cancer in women, and similar strategies are being explored for male patients. Understanding the biological differences in HER2-positive tumors between genders is crucial. Research indicates that male breast cancer may have different molecular characteristics compared to female counterparts, potentially affecting treatment responses. Therefore, it is essential to conduct studies specifically focused on male patients to ascertain the most effective therapeutic strategies. The role of combination therapies is gaining traction in the treatment of HER2positive breast cancer. Combining HER2-targeted agents with chemotherapy or other novel agents could enhance treatment efficacy and improve overall survival rates. Ongoing clinical trials are investigating these combinations, and their results could significantly impact treatment protocols for men diagnosed with this subtype. Another area of interest is the potential role of biomarkers in predicting treatment response in HER2-positive male breast cancer. Identifying specific genetic or molecular markers could help clinicians tailor therapies more effectively, ensuring that patients receive the most appropriate and effective treatment based on their tumor profile [10].

Hormone Receptor-Positive Breast Cancer:

Hormone receptor-positive breast cancer is characterized by the presence of hormone receptors (estrogen and/or progesterone) on the surface of cancer cells, which can fuel tumor growth. This subtype is particularly relevant for male breast cancer, as it opens up avenues for targeted hormonal therapies that can be effective in managing the disease. Understanding the nuances of hormone receptor expression in male patients is essential, as it may differ from that in females, potentially influencing treatment outcomes. One of the primary treatment options for hormone receptor-positive breast cancer is endocrine therapy, which includes medications such as tamoxifen and aromatase inhibitors. These

therapies work by blocking the effects of hormones on cancer cells or reducing hormone production in the body. However, the efficacy of these treatments in men requires further investigation, as studies have predominantly focused on female populations. Tailoring these therapies to account for the unique hormonal environments in men could enhance treatment effectiveness [11]. Additionally, the role of genetic testing in hormone receptor-positive male breast cancer is gaining importance. Identifying mutations in genes such as PIK3CA or alterations in the ESR1 gene may provide insights into resistance mechanisms to endocrine therapy. By understanding these genetic factors, clinicians can better predict which patients are likely to benefit from specific treatments and may consider alternative strategies for those who exhibit resistance. The psychosocial impact of a hormone receptor-positive breast cancer diagnosis in men should not be overlooked. Men may experience feelings of isolation or stigma due to societal perceptions of breast cancer as a female disease. Creating tailored support programs that address these emotional and psychological challenges is crucial. Support groups, counselling, and educational resources can empower male patients, helping them navigate their diagnosis and treatment journey more effectively. Ongoing research into the interplay between hormone receptor status and other molecular characteristics of male breast cancer is essential. Investigating how these factors interact can lead to more personalized treatment approaches, improving outcomes for male patients [12]. Hormonal influence on male breast cancer is a complex and multifaceted topic that warrants deeper exploration. While the focus has traditionally been on estrogen and progesterone receptors, emerging research suggests that androgens, the male hormones, may also play a significant role in the development and progression of breast cancer in men. Understanding how these hormones interact with breast cancer biology could lead to novel therapeutic strategies. For instance, the presence of androgen receptors in male breast cancer cells may influence tumor growth and response to treatment. Investigating the role of androgens could open new avenues for targeted therapies, potentially enhancing treatment effectiveness for male patients. Additionally, the interplay between hormone receptor status and the tumor microenvironment is an area ripe for exploration. Factors such as inflammation and the presence of other cell types in the tumor milieu could influence how hormone receptors function and how tumors respond to therapy. Furthermore, the psychological and emotional aspects of hormonal influence cannot be ignored. Men diagnosed with hormone receptor-positive breast cancer may grapple with feelings of vulnerability and confusion regarding their masculinity, especially in a society that often associates breast cancer with women. Addressing these concerns through targeted counseling and support services can help mitigate feelings of isolation and promote a more positive coping strategy. In terms of research, there is a pressing need for clinical trials that specifically include male patients with hormone receptor-positive breast cancer. Historically, clinical studies have predominantly involved female participants, which may limit the applicability of findings to male patients. By prioritizing male-inclusive research, we can better understand the unique biological and treatment responses in this population, ultimately leading to more effective and personalized care [13].

BRCA1 and BRCA2 Mutations:

BRCA1 and BRCA2 mutations are well-known genetic factors that significantly increase the risk of breast cancer in both men and women. While these mutations are often associated with female

breast cancer, their implications for male breast cancer are equally critical and deserve focused attention. Men carrying BRCA1 or BRCA2 mutations have a heightened risk of developing breast cancer, as well as other malignancies, such as prostate and pancreatic cancer. Understanding the prevalence of these mutations in the male population is essential for risk assessment and management. Genetic counseling and testing should be considered for men with a family history of breast cancer or other related cancers, as early identification of these mutations can lead to proactive surveillance strategies. For instance, men with BRCA2 mutations may benefit from regular screenings and discussions about preventive measures, including lifestyle modifications and potential prophylactic surgeries [14]. The presence of BRCA mutations can influence treatment decisions for male breast cancer patients. For example, those with BRCA2 mutations may respond differently to certain therapies, such as PARP inhibitors, which have shown promise in targeting cancers with specific genetic vulnerabilities. This highlights the importance of personalized medicine in the treatment of male breast cancer, where genetic profiles can guide therapeutic choices and improve outcomes. The psychosocial implications of being a male carrier of BRCA mutations are also significant. Men may experience anxiety and uncertainty regarding their health and the potential impact on their families. Educational programs that address these concerns can empower men to make informed decisions about their health and encourage open discussions within families about genetic risks. Moreover, there is a growing need for awareness campaigns that specifically target male breast cancer and its association with BRCA mutations. By highlighting the fact that men can also be affected by breast cancer, these initiatives can help reduce stigma and promote early detection. Engaging male patients in conversations about their health can foster a supportive community and encourage them to seek necessary medical advice without fear of judgment [15].

PARP inhibition:

PARP inhibition has emerged as a promising therapeutic strategy for treating male breast cancer, particularly in patients with BRCA1 and BRCA2 mutations. This class of drugs works by targeting the DNA repair mechanisms that are compromised in cancer cells harboring these mutations. By inhibiting the PARP enzyme, which plays a critical role in repairing single-strand breaks in DNA, these therapies can lead to the accumulation of DNA damage and ultimately result in cancer cell death. The efficacy of PARP inhibitors in male breast cancer highlights the importance of genetic profiling in treatment planning. For instance, male patients with BRCA mutations may experience significant benefits from these targeted therapies, which can be more effective than traditional chemotherapy options. This underscores the necessity of integrating genetic testing into routine clinical practice for male breast cancer patients, allowing for tailored treatment approaches that align with their unique genetic backgrounds. The exploration of PARP inhibitors in combination with other treatment modalities, such as immunotherapy or hormone therapy, presents an exciting frontier in male breast cancer management. Research into synergistic effects could lead to enhanced therapeutic outcomes and improved survival rates. As clinical trials continue to evaluate these combinations, it is crucial for healthcare providers to remain informed about emerging data and to consider these innovative strategies in their treatment plans [16]. Furthermore, the psychosocial impact of receiving PARP inhibitor therapy should not be overlooked. Patients may experience varying degrees of anxiety and

uncertainty regarding the side effects and long-term implications of these treatments. Providing comprehensive support services, including counselling and peer support groups, can help patients navigate these challenges and foster resilience throughout their treatment journey.

Antibody-Drug Conjugates:

Innovative treatment methods like Antibody-Drug Conjugates (ADCs) combine monoclonal antibodies with chemotherapy agents. The antibodies direct the chemotherapy specifically to cancerous cells, minimizing damage to healthy tissues and enhancing the therapeutic index of the treatment. This targeted approach is particularly beneficial for male breast cancer patients, as it can reduce the side effects commonly associated with traditional chemotherapy while maximizing the efficacy against malignant cells. The development of ADCs for male breast cancer is still in its early stages, but preliminary research shows promise in improving outcomes for patients with specific tumor markers. For instance, HER2-positive male breast cancer patients may benefit from ADCs that target the HER2 protein, which is overexpressed in some breast cancers. By leveraging the specificity of monoclonal antibodies, ADCs can deliver cytotoxic agents directly to cancer cells, sparing normal tissues and potentially leading to better tolerability and quality of life during treatment [17]. The integration of ADCs into treatment regimens could pave the way for more personalized approaches in male breast cancer therapy. As researchers continue to identify biomarkers that predict response to ADCs, clinicians can tailor treatments based on individual patient profiles, ensuring that each patient receives the most effective therapy for their unique cancer characteristics. In addition to the clinical benefits, the introduction of ADCs into the treatment landscape for male breast cancer also highlights the importance of ongoing research and development in this area. Advocacy for funding and support for clinical trials is crucial to advancing our understanding of male breast cancer and exploring innovative treatment options. Engaging the medical community and the public in discussions about the significance of male breast cancer research can foster a culture of awareness and urgency, ultimately leading to improved outcomes for affected individuals. The psychosocial aspects of undergoing treatment with ADCs should be addressed. Patients may have questions about the mechanism of action, potential side effects, and the overall treatment timeline. Providing clear, accessible information and resources can help demystify the process and alleviate concerns. Support groups specifically for male breast cancer patients can also create a safe space for sharing experiences and coping strategies, reinforcing the notion that they are not alone in their journey [18].

Benefits and risk:

The benefits and risks of gene-targeted therapy in male breast cancer are multifaceted and warrant careful consideration. On the positive side, gene-targeted therapies can offer highly personalized treatment options that specifically address the genetic abnormalities present in a patient's tumor. This precision medicine approach can lead to improved response rates and reduced toxicity compared to conventional therapies. For instance, patients with specific mutations may respond exceptionally well to targeted agents, resulting in better overall survival and quality of life. Gene-targeted therapies can potentially prevent the progression of the disease by addressing the underlying genetic factors that contribute to tumor growth. This proactive approach not only targets existing cancer cells but may also inhibit the development of new malignancies, particularly in

high-risk populations, such as those with BRCA mutations [19]. However, the risks associated with gene-targeted therapy must also be acknowledged. One significant concern is the potential for the development of resistance to these therapies over time. Cancer cells can adapt and evolve, leading to treatment failure and disease progression. Additionally, the long-term effects of these therapies are still being studied, and patients may experience unforeseen side effects that could impact their overall health and well-being. While these treatments hold great promise, they can be prohibitively expensive, and not all patients may have access to the necessary genetic testing or the therapies themselves. This disparity can lead to inequities in treatment outcomes, highlighting the need for advocacy and policy changes to ensure that all patients have equal access to cutting-edge cancer care. The emotional and psychological implications of undergoing gene-targeted therapy should not be underestimated. Patients may grapple with the uncertainty of their treatment's effectiveness and the potential for side effects, which can lead to increased anxiety and stress. It is essential for healthcare providers to offer comprehensive support, including counselling and education, to help patients navigate these challenges [20].

Future aspects and the Improvement:

Possible improvements for future research and treatment strategies in male breast cancer could focus on several key areas. First, enhancing collaboration between researchers, clinicians, and patient advocacy groups can lead to more comprehensive studies that address the unique challenges faced by male breast cancer patients. This interdisciplinary approach can foster innovative solutions and ensure that research is grounded in the real-world experiences of patients. Second, expanding genetic testing and screening protocols for male breast cancer is essential. By identifying at-risk individuals earlier, we can implement preventive measures and tailor treatment plans more effectively. Increased awareness among healthcare providers about the signs and symptoms of male breast cancer can also facilitate earlier diagnosis, which is crucial for improving outcomes. Third, integrating patient-reported outcomes into clinical trials can provide valuable insights into the effectiveness of treatments from the patient's perspective. Understanding how therapies impact quality of life, emotional wellbeing, and daily functioning can help refine treatment protocols and support services. Moreover, investing in education and outreach initiatives aimed at both the medical community and the general public can help destigmatize male breast cancer. By raising awareness about its occurrence and the importance of early detection, we can encourage more men to seek medical advice when they notice unusual symptoms. Finally, fostering a culture of inclusivity in clinical trials is vital. Historically, male breast cancer has been underrepresented in research, leading to gaps in knowledge about the disease. Ensuring that diverse populations are included in studies can help identify variations in treatment response and improve the applicability of findings across different demographics.

CONCLUSION:

While male breast cancer is a rare condition, its complexity and the unique challenges it presents warrant increased attention. By enhancing awareness, supporting research, and addressing the psychological needs of male patients, we can improve outcomes and quality of life for those affected by this disease. The landscape of male breast cancer treatment is evolving, with gene-targeted therapies at the forefront. Continued research, personalized treatment approaches, and a

focus on lifestyle factors will be crucial in improving outcomes for this underserved patient population. There is a pressing need for educational initiatives aimed at healthcare providers to enhance their understanding of male breast cancer. This knowledge gap can lead to misdiagnosis or under diagnosis, further complicating treatment pathways. Training programs that emphasize the unique aspects of male breast cancer can help clinicians recognize symptoms earlier and initiate appropriate genetic testing when warranted. Gene-targeted therapy represents a promising and highly personalized approach to treating male breast cancer. By targeting specific genetic and molecular changes, these therapies aim to effectively inhibit the growth of cancer cells while minimizing damage to healthy cells. Ongoing research continues to advance our understanding of the unique genetic profiles of male breast cancer, leading to the development of new and more effective targeted treatments. This personalized treatment strategy not only improves the chances of successful outcomes but also marks a significant advancement in the fight against male breast cancer. Tailoring therapy to the individual's genetic makeup ensures a more precise and effective treatment, paving the way for a future where cancer treatment is highly personalized and increasingly successful.

REFERENCES

1. Sirieix, Junien et al. (2020). Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)., 12. https://doi.org/10.1177/1758835920980548.
2. https://europepmc.org/articles/pmc130531?pdf=render
3. https://www.pnas.org/content/pnas/116/29/14573.
4. Co, Michael, Lee, Andrea, and Kwong, Ava (2020). Delayed presentation, diagnosis and psychosocial aspects of male breast cancer., 9(10), 3305-3309. https://doi.org/10.1002/cam4.2953.
5. https://cora.ucc.ie/bitstreams/b09c10ac-b2d84b26bae71ed881484d41/download.
6. Co, Michael, Lee, Andrea, and Kwong, Ava (2020). Delayed presentation, diagnosis, and psychosocial aspects of male breast cancer., 9(10), 3305-3309. https://doi.org/10.1002/cam4.2953.
7. https://www.pnas.org/content/pnas/116/23/11428.
8. Hussain, Maha et al. (2018). Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results from NCI 9012., 36(10), 991-999. https://doi.org/10.1200/jco.2017.75.7310.
9. Fernandez, Gerardo et al. (2022). Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years., 24(1). https://doi.org/10.1186/s13058-022-01592-2.
10. http://ejbc.kr/Synapse/Data/PDFData/0096JBC/jbc-22-141.
11. Watts, Eleanor L. et al. (2020). Circulating insulin - like growth factor - I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank.148(9),2274-2288. https://doi.org/10.1002/ijc.33416.
12. Duso, Bruno A. et al. (2020). Pharmacological management of male breast cancer.1493-1504. https://doi.org/10.1080/14656566.2020.1763305.
13. Auchus, Richard J., and Sharifi, Nima (2020). Sex Hormones and Prostate Cancer.,71(1) 33-

45. https://doi.org/10.1146/annurev-med-051418-060357.
14. CBIPM Genomics Team, undefined et al. (2019). Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse populationbased biobank.,12(1). https://doi.org/10.1186/s13073-019-0691-1.
15. Hesse-Biber, Sharlene, and An, Chen (2015). Within-Gender Differences in Medical Decision Making Among Male Carriers of the BRCA Genetic Mutation for Hereditary Breast Cancer.11(5), 14441459. https://doi.org/10.1177/1557988315610806.
16. Kim, Bumjun et al. (2021). A Lipid Targeting, pH‐Responsive Nano emulsion Encapsulating a DNA Intercalating Agent and HDAC Inhibitor Reduces TNBC Tumor Burden. 4(3). https://doi.org/10.1002/adtp.202000211.
17. Lambert, John M., and Chari, Ravi V. J. (2014). Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer.57(16), 6949-6964. https://doi.org/10.1021/jm500766w.
18. Hussain, Maha et al. (2018). Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results from NCI 9012. 36(10), 991-999. https://doi.org/10.1200/jco.2017.75.7310.
19. Abida, Wassim et al. (2020). Rucaparib in Men with Metastatic Castration Resistant Prostate Cancer Harbouring a or Gene Alteration.38(323763-3772. https://doi.org/10.1200/jco.20.01035.
20. Krzyszczyk, Paulina et al. (2018). The growing role of precision and personalized medicine for cancer treatment., 06(03n04),79-100. https://doi.org/10.1142/s2339547818300020.
21. Penedo, Frank J. et al. (2020). Technology-Based Psychosocial Intervention to Improve Quality of Life and Reduce Symptom Burden in Men with Advanced Prostate Cancer: Results from a Randomized Controlled Trial.
22. (5), 490-505. https://doi.org/10.1007/s12529-019-09839-7).

HOW TO CITE Preeti Bhunia*, Dr. Nakul Gupta, Dr. Md. Sarfaraz Alam, Kamal Bani, Aditi Singh, Aanchal Dahiya, Gene Target Therapy for Male Breast Cancer, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 5, 3606-3614. https://doi.org/10.5281/zenodo.15480408